

Research

Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection

Monica C Panelli^{*}, Mitchell E Stashower[†], Herbert B Slade[‡], Kina Smith^{*}, Christopher Norwood[§], Andrea Abati[¶], Patricia Fetsch[¶], Armando Filie[¶], Shelley-Ann Walters[‡], Calvin Astry[‡], Eleonora Aricó^{*}, Yingdong Zhao[¥], Silvia Selleri^{*#}, Ena Wang^{*} and Francesco M Marincola^{*}

Addresses: ^{*}Immunogenetics Section, Department of Transfusion Medicine, Clinical Center National Institutes of Health, Bethesda, MD 20892, USA. [†]The Clinical Skin Center of Northern Virginia, Fairfax, VA 22033, USA. [‡]3M Pharmaceuticals, St Paul, MN 55144-1000, USA. [§]Department of Dermatology, National Naval Medical Center, Bethesda, MD 20889, USA. [¶]Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA. [¥]Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA. [#]Universita' degli Studi di Milano, Department of Human Morphology, via Mangiagalli, 20133 Milan, Italy.

Correspondence: Francesco M Marincola. Email: Fmarincola@mail.cc.nih.gov

Published: 15 January 2007

Genome **Biology** 2007, **8**:R8 (doi:10.1186/gb-2007-8-1-r8)

The electronic version of this article is the complete one and can be found online at <http://genomebiology.com/2007/8/1/R8>

Received: 15 August 2006

Revised: 6 October 2006

Accepted: 12 January 2007

© 2007 Panelli et al.; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Imiquimod is a Toll-like receptor-7 agonist capable of inducing complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We hypothesized that the characterization of the early transcriptional events induced by imiquimod may provide insights about immunological events preceding acute tissue and/or tumor rejection.

Results: We report a paired analysis of adjacent punch biopsies obtained pre- and post-treatment from 36 patients with BCC subjected to local application of imiquimod ($n = 22$) or vehicle cream ($n = 14$) in a blinded, randomized protocol. Four treatments were assessed (q12 applications for 2 or 4 days, or q24 hours for 4 or 8 days). RNA was amplified and hybridized to 17.5 K cDNA arrays. All treatment schedules similarly affected the transcriptional profile of BCC; however, the q12 \times 4 days regimen, associated with highest effectiveness, induced the most changes, with 637 genes unequivocally stimulated by imiquimod. A minority of transcripts (98 genes) confirmed previous reports of interferon- α involvement. The remaining 539 genes portrayed additional immunological functions predominantly involving the activation of cellular innate and adaptive immune-effector mechanisms. Importantly, these effector signatures recapitulate previous observations of tissue rejection in the context of cancer immunotherapy, acute allograft rejection and autoimmunity.

Conclusion: This study, based on a powerful and reproducible model of cancer eradication by innate immune mechanisms, provides the first insights in humans into the early transcriptional events associated with immune rejection. This model is likely representative of constant immunological pathways through which innate and adaptive immune responses combine to induce tissue destruction.

Background

In 2004, Aldara™ (imiquimod 5% cream, 3M Pharmaceutical, St Paul, MN, USA) labeling was extended by the Food and Drug Administration to include treatment of superficial basal cell carcinoma (BCC) based upon randomized controlled trials demonstrating complete histological clearance in 78% to 87% of superficial BCC treated topically 5 days per week for 6 weeks [1,2]. Pilot-scale and investigator initiated trials had shown 90% to 100% clearance with q12 hours (twice per day) dosing [3].

Imiquimod belongs to a family of synthetic small nucleotide-like molecules with potent immuno-modulatory activity mediated through Toll-like receptor (TLR)-7 (and 8) signaling. When applied topically, these compounds display immune-mediated anti-tumoral activity without damaging normal tissues [1,3-7]. Imiquimod targets predominantly TLR-7 expressing plasmacytoid dendritic cells (pDCs) with secondary recruitment and activation of other DC and macrophage subtypes and induction of T helper₁ responses within three to five days of treatment [4]. Stimulation of pDCs through TLR-7/myeloid differentiation response gene 88 (My-D88)/IRF-7 signaling induces expression of interferon (IFN)- α , which appears to act upon natural killer (NK) cells and conventional dendritic cells (DCs) to stimulate IFN- γ , tumor necrosis factor (TNF)- α , monocyte chemoattractant proteins (MCPs) and other cytokines [5,8,9]. This immunological cascade leads within two weeks to apoptotic death of cancer cells and their substitution by a mononuclear cell infiltrate [3-5,8].

Although imiquimod function seems particularly associated with IFN- α -stimulated genes (ISGs) [10], it remains unclear whether this pathway is solely responsible for all the downstream effects ultimately resulting in tumor clearance. Indeed, a comprehensive and conclusive characterization of the events leading to tumor rejection based on a prospectively controlled study has never been reported. We previously characterized ISGs *in vitro* [11] and *in vivo* (Belardelli F and Arico' E, manuscript in preparation), compiling a road map for the interpretation of transcriptional surveys of biological conditions affecting the tumor microenvironment (Additional data file 1).

Here, we report a paired analysis of adjacent punch biopsies obtained pre- and post-treatment from 36 patients with BCC subjected to local application of imiquimod or a control cream in a blinded, randomized protocol.

Results

A total of 65 subjects were screened, but 27 were ineligible due to their pre-enrollment biopsy excluding BCC and 2 were ineligible for other reasons. A total of 36 subjects were eligible for the study and started treatment with either imiquimod ($n = 22$) or vehicle cream ($n = 14$) (Table 1). After unblinding,

treatment groups were color-coded to facilitate the discussion. Out of the subjects, 61% had nodular BCC, 17% superficial BCC, and 22% unspecified BCC. Of note is that all 4 subjects randomized to the imiquimod q12 hours \times 4 days group had nodular BCC. Post-treatment biopsies were taken <12 hours after last dose for 17% of subjects, >36 hours after the last dose date for another 17%, and between 18 and 30 hours after last dose for 33%. This variability was uncontrollable and due to patient compliance. The locations of the tumors were: 41% on the face; 25% on the extremities; 22% on the trunk; and 11% on either the neck or scalp. Furthermore, patient (P) 23 and P28 did not complete treatment, missing two placebo and one imiquimod dose, respectively. The imbalance in the distribution of the elapsed time between last treatment dose and post-treatment biopsy did not significantly affect the results except, possibly, for the q24 \times 8 (pink) cohort. Interestingly, at this early time point, already 9 of 22 imiquimod-treated BCCs were found to be clear of tumor cells, particularly among patients treated with the most intense schedule.

Quantitative PCR

At this early stage of treatment, no changes were observed in TNF- α and MCP-1 expression, in contrast with others' findings at later stages [5,8,9]. IFN- γ $2^{-\Delta\Delta CT}$ from baseline to end of treatment (EOT) was significantly increased compared to dose-matched controls at all but the earliest time point (q12 \times 2, orange group; Figure 1a). IFN- α followed a similar pattern but significance was observed only with the most intense regimen (q12 \times 4, blue group; Figure 1b).

Identification of treatment (imiquimod)-specific genes

Unsupervised analysis applying various filtering parameters failed to segregate samples according to treatment, suggesting that imiquimod affects an insufficient number of genes to alter the global transcript of BCC. A paired *t*-test (cut-off p_2 value < 0.05) was applied to identify genes differentially expressed by identical lesions before and after treatment within each cohort. For instance, the q12 \times 4 (blue) cohort differentially expressed 1,578 genes at EOT compared to paired pre-treatment samples. Reclustering of these genes demonstrated that most were similarly expressed by post-treatment samples treated with placebo, reflecting changes due to vehicle alone or the tissue repair induced by the adjacent pre-treatment biopsy. A node, however, contained 263 genes exclusively upregulated in all EOT imiquimod-treated samples (Figure 1c (part b), vertical blue bar). This cohort-based training/prediction analysis was repeated with the other three treatment regimens, providing independently similar results. In all cases, nodes were identified inclusive of genes uniquely expressed in EOT imiquimod-treated samples (Figure 1c (parts a and d); Additional data file 4). The number of imiquimod-induced genes varied among cohorts, however, with the largest amount in the q12 \times 4 (blue) cohort, in line with the higher clinical effectiveness of this intense dosing regimen [3]. There was extensive overlap among the genes

Table 1

Composition of study cohorts

Patient ID	Cohort	Doses received	EOT → B× time lapse (hours)	Histology	ΔCD8	ΔCD56	Tumor at EOT
P5	Imiq q12 × 2 days	4	13	Nodular	0	-I	+
P6	Imiq q12 × 2 days	4	14	Undetermined	0	0	+
P17	Imiq q12 × 2 days	4	36	Undetermined	NE	NE	-
P18	Imiq q12 × 2 days	4	33	Nodular	+I	0	+
P30	Imiq q12 × 2 days	4	16	Nodular	0	0	-
P38	Imiq q12 × 2 days	4	17	Nodular	0	0	+
P23I	Imiq q12 × 2 days	4	22	Undetermined	+I	0	+
P10	Vehic q12 × 2 days	4	12	Nodular	0	0	+
P23	Vehic q12 × 2 days	2	15	Nodular	+2	0	+
P26	Vehic q12 × 2 days	4	45	Nodular	0	0	+
Mean ± SD = 22 ± 11.5							
P1	Imiq q12 × 4 days	8	8	Nodular	0	0	+
P21	Imiq q12 × 4 days	8	41	Nodular	0	+I	+
P22	Imiq q12 × 4 days	8	11	Nodular	+I	0	-
P40	Imiq q12 × 4 days	8	17	Nodular	+I	+I	-
P42	Imiq q12 × 4 days	8	3	Undetermined	+3	0	-
P129	Imiq q12 × 4 days	8	19	Nodular	+I	0	+
P135	Imiq q12 × 4 days	8	21	Superficial	+I	+I	-
P41	Vehic q12 × 4 days	8	28	Nodular	+I	0	+
P134	Vehic q12 × 4 days	8	19	Nodular	+2	0	+
P8	Vehic q12 × 4 days	8	20	Nodular	0	0	+
P20	Vehic q12 × 4 days	8	16	Superficial	0	0	+
Mean ± SD = 18 ± 10.2							
P11	Imiq q24 × 4 days	4	26	Nodular	0	+I	+
P28	Imiq q24 × 4 days	3	20	Nodular	NE	NE	+
P112	Imiq q24 × 4 days	4	44	Nodular	0	0	+
P214	Imiq q24 × 4 days	4	51	Nodular	+2	+I	-
P4	Vehic q24 × 4 days	4	16	Superficial	NE	-I	-
P13	Vehic q24 × 4 days	4	30	Nodular	0	0	+
P36	Vehic q24 × 4 days	4	25	Superficial	0	0	+
Mean ± SD = 30 ± 12.8							
P233	Imiq q24 × 8 days	8	32	Undetermined	0	+I	+
P132	Imiq q24 × 8 days	8	159	Undetermined	0	+2	-
P24	Imiq q24 × 8 days	8	48	Superficial	+I	0	-
P3	Imiq q24 × 8 days	8	12	Undetermined	-I	0	+
P2	Vehic q24 × 8 days	8	6	Undetermined	0	-I	+
P15	Vehic q24 × 8 days	8	21	Nodular	0	0	+
P27	Vehic q24 × 8 days	8	26	Nodular	NE	NE	+
P137	Vehic q24 × 8 days	8	11	Superficial	0	0	+
Mean ± SD = 39 ± 50.3							

Punch biopsies are labeled according to patient number (P1 to P42) and timing of excision: PB0, pre-enrollment; PB1 and PB2, pre-treatment; PB3 and PB4, post-treatment. Biopsies from patients replacing drop-outs were labeled one digit to the serial number (that is, P101 to P142 or P201 to P242). PB1 and PB3 were collected for total RNA isolation; PB2 and PB4 for IHC. Undetermined refers to a BCC histology in-between superficial and nodular. ΔCD8 and ΔCD56 scores differences in infiltrate between EOT and pre-treatment samples (see Materials and methods). Tumor at EOT: identifiable (+) or not identifiable (-) tumor cells in the hematoxylin eosin stained EOT biopsy. Imiq, imiquimod; NE, not evaluated; Vehic, vehicle.

identified by the various comparisons (Figure 1c (part e)); 41 (63%) of 65, 40 (71%) of 56 and 16 (70%) of 23 genes differentially expressed in the orange, green and pink groups, respectively, were included among those identified as differentially expressed in the blue group. Reclustering of experimental samples based on imiquimod-specific signatures from each cohort suggested their independent predictive value in sorting imiquimod-treated BCC from pre-treatment and control samples as exemplified by the blue cohort signature, which clumped together not only the samples from the blue group, which served as a basis to select the genes used for clustering, but also 9 of the other 15 imiquimod-treated samples compared with only 3 of 14 vehicle-treated samples (Fisher p_2 value = 0.04). Four of the five samples that did not cluster together with the blue group samples belonged to the orange group (Figure 1d).

Thus, different dosing schedules differed quantitatively but not qualitatively, with the same genes being induced among them. The striking difference in number of genes induced between the $q12 \times 2$ (orange) and the $q12 \times 4$ (blue) cohorts strongly emphasizes the importance of the number of doses; however, the $q24 \times 8$ (pink) group, which received the same number of imiquimod applications as the blue group in twice the amount of time, displayed similar but dampened transcriptional changes, emphasizing the importance of administration to sustain the pro-inflammatory stimulus associated with the higher efficacy of the $q12$ schedule.

This analysis supports the specificity of our findings but also simultaneously emphasized the need to discriminate imiquimod-specific effects from those due to vehicle cream application and/or tissue repair induced by the adjacent pre-treatment biopsy. Because $q12$ dose scheduling had been observed previously to produce the highest rates of clearance [3], we adopted this cohort as the basis for further analysis. This selection offered the additional advantage of allowing

the largest number of temporally matched placebo-treated samples ($q12 \times 4$ and $q24 \times 4$ cohorts). At EOT, 1,578 genes were significantly altered in expression in the $q12 \times 4$ (blue) cohort compared to pre-treatment (paired t -test cut-off p value < 0.05; Figure 2a). To eliminate placebo and/or surgical bias, an unpaired t -test (cutoff p value < 0.05) was applied to this gene pool, identifying transcripts differentially expressed between imiquimod-treated EOT samples and vehicle cream-treated samples. This analysis left 637 genes unequivocally modulated by imiquimod (Figure 2b,c; Additional data file 3). A global test was applied to this gene set to test the likelihood of getting this proportion of significant genes by chance (at the 0.05 level) if there were no real differences between the two classes. Such likelihood was negligible, with a permutation p value of 0.001. The false discovery rates (FDRs) of the differentially expressed genes are less than 11.9%. To estimate the specificity/accuracy of the 637 'imiquimod-induced' genes, we considered as a training set the samples utilized for their identification ($q12 \times 4$ days treatment group and the $q12 \times 4$ and $q24 \times 4$ days vehicle groups; Figure 2b). The trained predictors were then used to segregate post-imiquimod treatment samples from pre-treatment or vehicle treated samples belonging to the other groups. This analysis was performed using the Support Vector Machines (a supervised learning algorithm that classifies data by finding optimal fit between different statistical classes); this analysis yielded a sensitivity of 60%, specificity of 92% and an overall accuracy of 82.4%. Thus, the set of 637 genes identified by this study represent a highly specific functional signature of imiquimod-induced changes during the early stages of therapy in lesions whose transcriptional profiles were sufficiently activated. The relatively low sensitivity of the gene set as predictors most likely reflects the exclusion of lesions in the earliest cohort (orange group) that were not exposed sufficiently to imiquimod.

Of the 637 genes, 65 were also significantly altered in expres-

Figure 1 (see following page)

Differential expression of IFN- γ and IFN- α in EOT compared to pre-treatment samples in all cohorts; hierarchical clustering based on genes differentially expressed at EOT compared to pre-treatment samples in each treatment cohort and dendrogram showing the degree of relatedness of samples based on imiquimod-induced genes in the blue group. The $2^{-\Delta\Delta CT}$ describes (a) IFN- γ and (b) IFN- α gene expression fold change at EOT relative to baseline after normalization according to the endogenous reference cyclophilin G. C_T equals the mean cycle times of duplicate wells and $\Delta\Delta C_T = (C_T, \text{Target} - C_T, \text{cyclophilin})_{\text{EOT}} - (C_T, \text{Target} - C_T, \text{cyclophilin})_{\text{baseline}}$. The fold-change data were transformed using \log_{10} . The box and whisker style box plot gives the median and interquartile range (box), 1.5 of the inter-quartile range (whiskers), points outside the whiskers (square symbols) and the mean (cross symbol). Statistics: p values refer to 2-sample t -tests between treatment and control groups. (c) Based on a paired t -test cut-off p_2 value < 0.05, 1,311 genes were differentially expressed between the pre-treatment and EOT samples in the $q12 \times 2$ (orange) cohort. Reclustering of these genes identified a node of 65 genes uniquely upregulated in the imiquimod-treated EOT samples (part i). Similar analyses were performed for the other imiquimod-treated cohorts; 1,578 genes were differentially expressed in the $q12 \times 4$ (blue) cohort, including an imiquimod-specific node of 263 genes (part ii and the vertical blue bar in adjacent complete data set); 650 genes were differentially expressed in the $q24 \times 4$ (green) cohort, including an imiquimod-specific node of 58 genes (part iii); and 495 genes were differentially expressed in the $q24 \times 8$ (pink) cohort, including an imiquimod-specific node of 23 genes (part iv). A Venn diagram displays the extent of overlap among genes differentially expressed in the three most informative orange, blue and green groups (part v). (d) Reclustering of all BCC samples based on the imiquimod-specific 263-gene signature identified in the $q12 \times 4$ (blue) cohort. Straight lines identify imiquimod-treated EOT samples color coded according to treatment regimen; dashed lines identify vehicle cream-treated EOT samples and unlabeled are the all pre-treatment samples. A diagram illustrating the strategy used to prepare Figure 1c,d is available as Additional data file 4.




Figure 1 (see legend on previous page)

sion in the $q12 \times 2$ (orange) cohort; we refer, therefore, to these as 'primary' responders to imiquimod and to the rest as 'secondary'. Finally, the 637 genes were matched to our database of IFN- α -related signatures consisting of 426 genes identified using the same cDNA platform and reference system in monocytes stimulated with various IFN- α subtypes *in vitro* [11] and/or induced *in vivo* by systemic IFN- α_{2b} therapy. Only 98 (22 included among the primary) genes matched the database and were considered *bona fide* ISGs. The primary ISGs included *STAT-1*, *MX1*, *MX2* and *IFITM1*. By four days, secondary ISGs had broadened to *STAT2*, *IRF-2* and *IRF7*, *JAK-2* and *JAK-3* and *N-myc interactor (NMI)*. Moreover, *CXCL10/IP-10* was significantly upregulated; *CXCL10* is a monocyte and T lymphocyte chemoattractant interacting with the chemokine receptor CD183 (*CXCR3*) and T-cell CD26. The remaining 539 genes were induced through IFN- α -independent pathways, suggesting that only a small proportion of the effector activity of imiquimod is mediated by IFN- α .

Primary non-IFN- α -stimulated genes

By the second day of $q12$ imiquimod treatment, 65 primary non-ISGs were identified, echoing predominantly innate immune effector functions (Figure 3a). *CXCR3*, a ligand for IP-10 and monokine induced by IFN- γ (*MIG/CXCL9*) was the earliest upregulated cytokine receptor, suggesting its early involvement in the crosstalk leading to migration and activation of monocytes and lymphocytes. Also induced by IFN- γ were several HLA class I and class II transcripts, including HLA-B and HLA-DR β 1. Transcripts critical for the activation of innate immune effector cells, such as NK cells and mononuclear phagocytes, were highly expressed; for example, *TYROBP*, a killer-cell immunoglobulin-like receptor family member and cytochrome β -245, a component of phagocytes' lytic function. Activation of macrophages was also strongly supported by the upregulation of CD68, and the modulation of complement component 1 $q\alpha$ (*C1QA*) and *MY-D88* [12]. The induction of CD37 represented an early sign of the transition from an innate to an adaptive immune response as CD37 regulates T cell proliferation through TCR signaling [13]. Finally, Caspase 10 upregulation suggests an early initiation of apoptotic mechanisms.

Secondary non-IFN- α -stimulated genes

The vast majority of transcriptional effects were observed four days after $q12$ treatment (Figure 3b), when the inflam-

matory process is amplified by the induction of cytokines, their receptors and genes related to their interactions, such as dual specificity phosphatase 5 (*DUSP-5*) and the gene encoding the anti-apoptotic *BCL2*. The induction of pro-inflammatory molecules was strongly reminiscent of the broad transcriptional changes induced by the *in vitro* stimulation of peripheral blood mononuclear cells (PBMCs) by interleukin (IL)-2 [14]. In particular, the upregulation of cytokines and corresponding receptors within the common γ chain receptor family (particularly IL-15 and the IL-15 receptor α -chain, the IL-2/IL-15 receptor β -chain and the common γ chain itself; Figure 3b) suggest early activation within the tumor microenvironment of CD8 T and NK cells [15,16]. This notion is also supported by the modulation of downstream transcription factors of IL-2/IL-15 receptor triggering, such as Jak kinases, *STAT-1*, *STAT-3* and *STAT-5*, and the upregulation of T cell receptor subunits, cytotoxic granules and NK-activation receptors (Figure 3b). The increased expression of the chemokine (C-C motif) receptor 7 (*CCR-7*) also supports a potent activation of pro-inflammatory signals; *CCR7* is expressed by activated B and T lymphocytes and NK cells and controls their migration to inflamed tissues [17]. *MIG* is a chemoattractant for *CXCR3*-bearing immune cells that may contribute, together with IP-10, to the intensification of the acute inflammatory process. Monocyte inflammatory protein (MIP)-1 α (*CCL3*), MIP-1 β (*CCL4*) and MCP-3 (*CCL7*) were also induced at this point. Among them, MCP-3 has been shown to augment monocyte anti-tumor activity while *CCL3/MIP-1 α* and MIP-1 β represent potent pro-inflammatory factors with chemotactic properties for neutrophils and DC and NK cells. Interestingly, CD64 and the low-affinity IgG Fc receptor II-B (*FCGR2B*), which were also upregulated among the secondary non-ISGs (Figure 3c), have been shown to stimulate MIP-1 α and MIP-1 β release [18].

Cytotoxic T and NK cell signatures

The most striking effects of imiquimod were on cytotoxic mechanisms, with the induction of NK cell gene-5 (*NKG-5*), NK cell protein-4 (*NK4*)/IL-32 granzyme-B, -A and -K, perforin and lymphotoxin- β receptor [19,20]. (Figure 3b,c). Moreover, the concomitant transcription of several caspases indicate active cytotoxicity [20] combined with granule-mediated apoptosis suggested by the upregulation of proteoglycan 1 secretory granule (*PRG1*) [21].

Figure 2 (see following page)

Identification of treatment (imiquimod)-specific transcripts in the most intensive schedule ($q12 \times 4$ ($q12,4d$), blue cohort). (a) A pairwise *t*-test (p value < 0.05) was applied to identify genes differentially expressed between pre-treatment and EOT biopsies from the same BCC belonging to the $q12 \times 4$ (blue) cohort. The 1,578 genes identified were then tested for treatment specificity by identifying those differentially expressed between the blue group treated with imiquimod (TX) compared with temporally matched, vehicle control-treated EOT biopsies (combined blue and green groups) (b) The remaining 637 treatment-specific genes were classified based on their significant expression also in the earlier $q12 \times 2$ (orange) group as primary (65 genes) while the other ones were considered secondary. Finally, the same genes were also compared to a database of IFN- α -associated transcripts as described in the Materials and methods. In the same panel the 637 genes are shown in a supervised-sample hierarchical clustering of the genes. (c) Legend of samples, dashed and solid bars identify vehicle control or imiquimod-treated samples, respectively.

Several T cell receptor signaling and amplification-associated genes were also upregulated, including those encoding TCR- α , - β and - γ chains, ζ -chain (ZAP70), CD3Z, T cell immune-regulator 1 and related co-receptor CD5 [22,23]. Moreover, CD2/LFA-2 mediates T and NK cell activation through interactions with CD59, which is also upregulated at this time point [24,25]. Similarly, the overexpression of CD69 marks the activation of T and NK cells and it has been correlated by Posselt *et al.* [26] with acute renal allograft rejection.

Several transcripts suggest a primary involvement of NK cells in the process, such as the NKG2 family of genes, which encode receptors that are expressed on most NK cells [27]: killer cell lectin-like receptor subfamily C, member 2 (KLRC2/NKG2C), member 3 (KLRC3/NKG2E), and member 4 (KLRC4/NKG2F). Moreover, all NK receptor adapter proteins containing an immune-receptor tyrosine based activation motif (ITAM) were found to be upregulated (FCER1g), CD3z and TYROBP/DAP12. The upregulation of KLRC2/NKG2C, TYROBP/DAP12 and FCER1G suggests the occurrence of NK and T cell activation, which would lead to release of pre-made cytotoxic granules and secretion of cytokines [27]. Another NK cell-related gene is that encoding Cathepsin w, a cysteine proteinase associated with the membrane and the endoplasmic reticulum of NK and T cells and regulation of their cytolytic activities [28]. Finally, the minor histocompatibility antigen HA-1 may be one of the immunodominant stimulators of graft-versus-host and graft-versus-malignancy effects through increasing cytotoxic mechanisms [29].

Markers of immune infiltrates

Transcriptional analysis portrayed a predominant enhancement of immune infiltrates associated with T and NK cells. Because 9 of 22 imiquimod-treated BCCs were cleared of tumor cells at EOT it was impossible to further analyze whether the identified changes were occurring in specific histological areas as sharply defined in pre-treatment lesions. In such cases, changes in immune infiltrates were calculated comparing EOT results with pre-treatment peri-tumoral infiltrates. With all four imiquimod treatment groups pooled together, significant increases were noted in CD56 (NK cells), CD4 and CD8 T cells, with CD56 (NK cells) showing significant difference relative to the pooled vehicle group (Table 2, Figure 4). Moreover, BCL-2 expression was selectively enhanced in immune but not cancer cells. Importantly, enhancement of CD8 expression was strongly dependent upon treatment schedule, with 5 of 7 subjects treated in the

q12 \times 4 (blue) cohort experiencing increases in the number of CD8 T cells (p value < 0.05). Other markers did not reach statistical significance, including those associated with cytotoxic activity, such as granzymes and perforin, suggesting that the differences identified at the transcript level may precede changes detectable as protein expression, as we recently observed studying transcript to protein relationships in IL-2-stimulated PBMCs [14]. These data confirm the transcriptional observation that imiquimod primarily induces recruitment and activation of T and NK cells within the BCC microenvironment.

Discussion

This is the first prospectively controlled study conducted to identify the early biological events associated with the eradication of BCC through an immune-mediated mechanism. By protocol design, tumor regression did not represent an endpoint and tumors were removed at the end of the study. Thus, the association between the molecular/genetic findings and tumor clearance is presumptive, based on the historical 80% to 90% clearance rates recognized by the Food and Drug Administration for the release of imiquimod for clinical use [2]. However, it is interesting to note that 9 of 22 (41%) imiquimod-treated BCCs were devoid of cancer cells by EOT (2 to 8 days from beginning of treatment) while only 1 of 14 (7%) control-treated BCCs had no identifiable tumor cells (Fisher test p value = 0.05), suggesting that artifacts due to vehicle administration or surgical trauma were not responsible for the early tumor clearance.

As indicated by qPCR, IFN- γ transcription was more prevalent than IFN- α transcription. This is in line with the evidence of predominant NK, CD8 and CD4 T cell activity in this study. Sullivan *et al.* [30] had indeed previously observed similar cellular infiltrates (particularly CD4 and CD56 expressing cells) in a smaller, open-label, matched controlled, non-randomized study in which six patients with BCC treated with imiquimod at daily intervals for a total of ten administrations were compared with six patients receiving comparable vehicle cream treatment. The predominance of IFN- γ transcription suggests that pDCs trigger other immune functions through the production of IFN- α , which in turn activates resident T and NK cells, selective producers of IFN- γ [31]. We hypothesize that these secondary immune effector mechanisms induce destruction of target cells, providing antigen to professional antigen presenting cells for priming of naive T-cells in draining lymph nodes [31,32]. Indeed, several of the

Figure 3 (see following page)

Visual display of selected treatment (imiquimod)-specific transcripts (complete database available on line). **(a)** Display of selected primary treatment-specific genes identified as per Figure 2. **(b)** Secondary treatment-specific genes related to effector functions with primary focus on cytokines, cytokine receptors and lytic enzymes. **(c)** Secondary treatment-specific genes representative of cell surface markers, receptors and associated molecules. In red are genes whose expression was found to be associated with acute renal allograft rejection [37]. Treatment cohorts are described by the bars on top of each cluster.





Figure 3 (see legend on previous page)

**Figure 4**

IHC staining for CD56 and CD8 in BCC from (a) P40 (imiquimod treated) and (b) P8 (vehicle-control). Lesions were graded blindly by two pathologists (AA and AF) and graded before and at EOT for peri-tumoral and intra-tumoral immune cells infiltrate. Cancer cells were evaluated separately for each marker. When BCC was absent at EOT as in P40 the immune infiltrate was compared to the peri-tumoral pre-treatment infiltrate. NE, not evaluable because no tumor cells were left at EOT.

transcripts associated with imiquimod treatment show activation of T and NK cells and induction of IFN- γ stimulated genes (Figure 3). The cytotoxic T and NK cell signatures identified here (granzymes, perforin and other NK cell-related genes) have recently been described in a mouse model of IFN- α and IFN- γ -producing killer DCs (IKDCs) [33], which simultaneously display cytotoxic and pro-inflammatory functions. Thus, IKDCs could summarize in a cellular unit our findings of ISG activation combined with broader cytotoxic and pro-inflammatory properties. At present, IKDCs have not been characterized in humans, nor it is known whether they express TLR-7; future studies should address their role as putative mediators of immune rejection.

Imiquimod treatment stands as a unique opportunity to study the mechanisms of immune-mediated rejection directly in human tissues. This TLR-7 agonist links multiple immune pathways. Of these, IFN- α plays a consistent but not exclusive role. Previous transcriptional surveys have provided a broad view of the biological processes associated with immune-mediated tissue destruction, identifying convergent characteristics. Neoplastic inflammation approaches the unresolving process of chronic hepatitis C virus (HCV) infection where the presence of antigen-specific immune responses do not lead to clearance of the pathogen in the majority of cases [34,35]. Both diseases are characterized by the expression of ISGs that do not seem sufficient to clear the pathogenic process. Similar signatures can be identified in

Table 2**Scoring of immune infiltrate by immuno histochemistry**

Pooled treatment groups	Δ Score post - pre-treatment							Within group p value
	-3	-2	-1	0	1	2	3	
CD56								
Imiquimod	0	0	1	12	6	1	0	0.03
Vehicle	0	0	2	11	0	0	0	0.17
CD8								
Imiquimod	0	0	1	10	7	1	1	0.01
Vehicle	0	0	0	9	1	2	0	0.22
CD4								
Imiquimod	0	0	1	12	7	0	0	0.03
Vehicle	0	0	2	5	4	1	0	0.22
BCL-2								
Imiquimod	0	0	1	11	6	2	0	0.02
Vehicle	0	0	2	9	1	1	0	0.72

P values associated with the paired t-test for within group shifts relative to baseline. Δ Score refers to differences in infiltrate between EOT and pre-treatment samples using the scoring scale described in Materials and methods (IHC section).

liver biopsies from patients with chronic HCV infection [36] and in chronic allograft rejection controlled with standard immune suppression [37]. ISGs are also consistently expressed in melanoma metastases following the systemic administration of IL-2 independent of clinical outcome [38]. Thus, it appears that ISGs are part of immunological processes associated with chronic inflammation insufficient to clear its cause. On the contrary, several non-ISGs identified by this study delineate potent inflammatory (CCL7/MCP-3, CCL4/MIP- β , and so on) and cytotoxic (granzymes, perforin, NKG-5, and so on) functions rarely observed in chronically inflamed tissues but described in the acute inflammation associated with destruction of a tumor [38] or allograft [37], liver damage in HCV-induced cirrhosis [36] or gut dysfunction during flares of Crohn's disease [39]. This study corroborates the impression that immune-mediated tissue destruction comprises at least two components: a baseline cluster of ISGs that may be necessary but insufficient to induce tissue rejection and a less common activation of broad cytotoxic and other potent pro-inflammatory innate immune effector functions that are more tightly associated with rejection. Our findings are supported by the recent description of clearance of established cancers by the adoptive transfer of innate immune effector cells in the powerful model of spontaneous regression/complete resistance mice [40].

Sarwal M *et al.* [37] reported strikingly similar results evaluating the transcriptional behavior of renal cell allograft during acute rejection, basing the analysis on a similar array platform and utilizing the same RNA amplification method [41] (Figure 3, transcripts labeled in red). In spite of these similarities, they also reported a B cell signature characterized by enhanced expression of CD20 and several immunoglobulins that we did not identify in our study. This discrepancy could be explained by a specific role that B cell-

mediated immunity may play in the context of allo-recognition. In the case of BCC, the strong pro-inflammatory stimulus induced by imiquimod through TLR-7 signaling might bypass the requirement for an endogenous, tissue specific insult responsible for the secondary triggering of the cellular immune effector mechanisms identified by both studies. The signatures identified by both studies also match the anecdotal identification of the same genes in a melanoma metastasis that underwent regression following systemic IL-2 therapy [38].

Among the genes mutually reported by the previous three studies, NK4/IL-32 was recently recognized as a central mediator of Crohn's disease [42] and associated with liver damage during HCV infection [36]. NK4/IL-32 is a potent inducer of pro-inflammatory cytokines and it is selectively expressed by immune cells stimulated with IFN- γ IL-2 or the combination of IL-12 and IL-18 [14,39]. Indeed, we found NK4/IL-32, together with other genes associated with cytotoxic function, to be constitutively expressed by NK cells but only by activated CD8+ T cells [43]. Moreover, we recently observed NK4/IL-32 to be preferentially expressed in metastatic melanoma compared with other less immune responsive cancers [44]. It is possible that NK4/IL-32 may play a central role during imiquimod treatment by amplifying inflammatory stimuli through the induction of a cytokine cascade. Thus, this novel cytokine emerges as a central player in immune rejection or autoimmunity.

Dermatologists have long used imiquimod to treat BCC [4,45,46] Imiquimod mimics the action of single-stranded viral RNA [31], activating a pro-inflammatory cascade as a chemical prototype of the danger model of immune activation [47]. Meanwhile, tumor immunologists have struggled to

explain the paradoxical co-existence of tumor antigen-specific T cells induced by vaccination with growing tumor tissues. Indirect evidence suggests that vaccine-induced T cells reach the tumor site [48] and recognize tumor cells producing IFN- γ . However, this is not sufficient for tumor rejection since other effector mechanisms are not simultaneously activated [49] because cancers do not provide the danger signal necessary for full implementation of the immune responses [50]. Thus, immunization successfully affects the afferent loop of the immune response by eliciting TA-specific T cells but cannot affect T cell activation at the receiving end [51,52]. The cancer specificity of TLR agonists consists of the preferential attraction of TLR-7 expressing pDCs to chronically inflamed tissues and their enhanced recruitment [53]. Similar conclusions were recently reached by Torres *et al.* [54], who followed the biological events induced by imiquimod when administered to patients with actinic keratosis. Thus, TLR agonists exemplify how the gap between the induction of TA-specific T cells by immunization and their activation at the receiving end could be closed. It is thus conceivable that preparations of TLR agonists suitable for systemic administration may be used in the future as single agent therapy for other tumor types (trials are currently ongoing in Europe for melanoma) or as adjuvants to enhance the effectiveness of active-specific immunization approaches [55-57].

Conclusion

This study stands as a proof of principle that, when tissues are easily accessible, mechanistic observation about the effects of a treatment can be easily performed in humans by combining minimally invasive techniques (fine needle aspirates, through cut or punch biopsies) with high-fidelity mRNA amplification; such approaches are fundamental to refresh scientific hypotheses through direct human observation. Second, it provides insights into the early events leading to tumor rejection in a most powerful human model. Finally, it suggests that immune-mediated tumor rejection is only one aspect of tissue-specific destruction, which follows a constant immunological pathway shared by other anti-cancer immunotherapies, acute allograft rejection, autoimmune disease and tissue damage during chronic pathogen infections.

Materials and methods

Detailed methods are available as Additional data file 2.

Study design and patient information

This double-blind, placebo-controlled, randomized, parallel group clinical trial sponsored by 3M Pharmaceuticals and registered before patient enrollment (3M/NNMC study #1454-IMI) was designed to evaluate the early transcriptional events induced by topical imiquimod administration.

The trial was conducted at the National Naval Medical Center (Bethesda, MD, USA) in compliance with the Code of Federal Regulations and the guidelines for Good Clinical Practice. Imiquimod (5%, 12.5 mg) or vehicle cream were supplied in single-use 250 mg sachets. Following biopsy confirmation and time for healing, subjects applied a sufficient quantity of cream to cover the entire BCC and an area approximately 2 cm around. Each dose was left on the skin for eight hours. For the study, 48 subjects were supposed to be randomized in a 2:1 ratio to either imiquimod or vehicle within each of 4 dosing regimens (q12 hours for 2 or 4 days or q24 hours for 4 or 8 days). Subjects were randomized at the time of screening when the pre-enrollment biopsy was taken. Once eligibility was determined based on the biopsy result, the investigator contacted the subject, who either started treatment on a date instructed by the investigator or returned the study drug. Replacement subjects were identified for all subjects with a biopsy result negative for BCC or who discontinued prior to EOT procedures. BCCs were to be at least 7 mm diameter and were to be located on the scalp, face, trunk or proximal extremities. Punch biopsies (PB; 2 mm diameter) were obtained pre-enrollment to verify the diagnosis of BCC, pre-treatment (PB1 and PB2) and at EOT (PB3 and PB4), approximately 24 hours after the last dose taken. PB1 and PB3 were transferred immediately at the bedside into cryovials with 2 μ l RnAlater (Ambion, Austin, TX, USA), frozen in liquid nitrogen and stored at -80°C for total RNA isolation. PB2 and PB4 were placed in a cryomold, filled with OCT compound (Tissue-Tek, Elkhart, IN, USA), frozen in liquid nitrogen and stored at -80°C for immunohistochemistry (IHC).

RNA isolation and amplification and cDNA arrays

Total RNA was isolated with RNeasy minikits (Qiagen, Germantown, MD, USA) and amplified into anti-sense RNA as previously described [41,58,59] with the following modifications to minimize RNA degradation by abundant skin RNAases. Samples were homogenized in disposable tissue grinders (Fisher Scientific, Lafayette, CO, USA). Proteins potentially interfering with RNA isolation were removed by incubating the homogenate in 590 μ l distilled water and 10 μ l PROTEINASE K solution (Qiagen) at 55°C for 10 minutes then centrifuged at ambient temperature for 3 minutes. Supernatants were combined with 0.5 volumes of ethanol (96% to 100%) into a Rnase-Dnase free tube and RNA was isolated through a RNeasy mini column. First strand cDNA synthesis was accomplished in 1 μ l SUPERase \cdot In (Ambion) and ThermoScript RT (Gibco BRL, Gaithersburg, MD, USA) in 2 μ g bovine serum albumin. RNA quality was verified by Agilent technologies (Palo Alto, CA, USA). Anti-sense RNA was used for probe preparation or quantitative real-time PCR (qPCR). For microarray analysis, test samples were labeled with Cy5-dUTP (Amersham, Piscataway, NJ, USA) and co-hybridized with reference pooled normal donor PBMCs labeled with Cy3-dUTP to custom made 7 K-cDNA microarrays [60]. Arrays were scanned on a GenePix 4000 (Axon Instruments, Union City, CA, USA) and analyzed using Clus-

ter and Tree View software [61]. Gene ratios are presented according to the central method for display [62]. Gene annotations were mined using web-based tools such as DAVID [63], GeneCards [64], COPE [65] and Bioinformatic Harvester [66].

Quantitative PCR

QPCR was applied to detect the expression of IFN- α , IFN- γ , TNF- α and MCP-1 using an ABI Prism 7900 HT (Applied Biosystems, Foster City, CA, USA). Primers and probes were custom-designed to span exon-intron junctions and generate <150 base-pair amplicons (Biosource, Camarillo, CA, USA). Taqman probes were labeled at the 5' and 3' ends with the reporter FAM (6-carboxyfluorescein; emission $\lambda_{\text{max}} = 518$ nm) and the quencher TAMRA (6-carboxytetramethylrhodamine; emission $\lambda_{\text{max}} = 582$ nm), respectively. Standard curves were based on amplicons generated from human leukocyte antigen (HLA)-A*0201 expressing lymphocytes stimulated with IL-2 (300 IU/ml) and Flu M1:58-66 peptide; copy numbers were estimated with Oligo Calculator [67]. Linear regression R^2 -values pertinent to all standard curves were ≥ 0.98 . QPCR reactions were conducted in a 20 μ l volume, including 1 μ l cDNA, 1 \times Taqman Master MIX (Applied Biosystems), 2 μ l of 20 μ M primer and 1 μ l of 12.5 μ M probe. Thermal cycler parameters included 2 minutes at 50°C, 10 minutes at 95°C and 40 cycles involving denaturation at 95°C for 15 s, annealing-extension at 60°C for 1 minute. The $2^{-\Delta\Delta CT}$ method was utilized to compute fold change in gene expression at EOT relative to baseline after normalization according to cyclophilin G expression [68].

Immunohistochemistry

After confirming the presence of epidermis, dermis and tumor using hematoxylin and eosin, IHC was performed by staining 7 mm consecutive acetone-fixed sections for the expression of CD4, CD8, CD56, CD95, FasL, granzyme A and B, perforin, BCL-2, TRAIL, caspase 3 and PARP. Secondary staining consisted of biotinylated goat-anti-mouse IgG followed by avidin-biotin-peroxidase. A semi-quantitative estimation was conducted to separate histological entities as: tumor cells; intra-tumoral immune infiltrate; and peritumoral immune infiltrate. Scoring was assigned independently by two blinded pathologists (AA and AF) as: 0 (none), 1+ (few), 2+ (moderate), 3+ (numerous). Data are presented as shift in scores at EOT compared to baseline.

Statistics

Significance testing was based on paired or 2-sample two-tailed Student *t*-test as appropriate. *P* values < 0.05 were considered statistically significant. No adjustment was made for multiple comparisons. Fisher exact test was used to test the level of significance comparing the frequency of events between treatment groups. All analyses related to class comparison and class prediction was done using the BRB-Array Tools [69] developed by Simon [70]. Microarray raw data were curated according to GEO (series # GSE5121) [71].

Additional data files

The following additional data are available with the online version of this paper. Additional data file 1 provides a list of genes previously shown to be associated with the stimulation of various cell types with IFN- α . Additional data file 2 is an extended version of the Materials and methods, providing full disclosure of the methodology used. Additional data file 3 provides a complete list of the 637 genes specifically induced by imiquimod treatment based on the statistical approach presented in the text. Additional data file 4 is a diagram illustrating the mining strategy that was implemented for the preparation of Figure 1c,d.

References

- Schulze HJ, Cribier B, Requena L, Reifemberger J, Ferrandiz C, Garcia Diez A, Tebbs V, McRae S: **Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.** *Br J Dermatol* 2005, **152**:939-947.
- National Cancer Institute: Drug Information Summaries** [<http://www.cancer.gov/clinicaltrials/developments/newly-approved-treatments>]
- Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W: **The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview.** *Br J Dermatol* 2003, **149**(Suppl 66):53-56.
- Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R: **Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo.** *Arch Dermatol* 2003, **139**:1325-1332.
- Stanley MA: **Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential.** *Clin Exp Dermatol* 2002, **27**:571-577.
- Naylor MF, Crowson N, Kuwahara R, Teague K, Garcia C, Mackinnis C, Haque R, Odom C, Jankey C, Cornelison RL: **Treatment of lentigo maligna with topical imiquimod.** *Br J Dermatol* 2003, **149**(Suppl 66):66-70.
- Ray CM, Kluk M, Grin CM, Grant-Kels JM: **Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream.** *Int J Dermatol* 2005, **44**:428-434.
- Hurwitz DJ, Pincus L, Kupper TS: **Imiquimod: a topically applied link between innate and acquired immunity.** *Arch Dermatol* 2003, **139**:1347-1350.
- Majewski S, Marczak M, Mlynarczyk B, Benninghoff B, Jablonska S: **Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis.** *Int J Dermatol* 2005, **44**:14-19.
- KEGG PATHWAY Database** [<http://www.genome.ad.jp/kegg/pathway.html>]
- Stroncek DF, Basil C, Nagorsen D, Deola S, Arico E, Smith K, Wang E, Marincola FM, Panelli MC: **Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms.** *J Transl Med* 2005, **3**:24.
- KEGG: Toll-like Receptor Signaling Pathways** [http://www.genome.jp/dbget-bin/www_bget?path:hsa04620]
- van Spruiel AB, Puls KL, Sofi M, Pouniotis D, Hochrein H, Orinska Z, Knobloch KP, Plebanski M, Wright MD: **A regulatory role for CD37 in T cell proliferation.** *J Immunol* 2004, **172**:2953-2961.
- Jin P, Wang E, Provenzano M, Deola S, Selleri S, Voiculescu S, Stroncek DF, Panelli MC, Marincola FM: **Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets.** *J Transl Med* 2006, **4**:26.
- Schluns KS, Stoklasek T, Lefrancois L: **The roles of interleukin-15 receptor alpha: trans-presentation, receptor component, or both?** *Int J Biochem Cell Biol* 2005, **37**:1567-1571.
- Zambricki E, Shigeoka A, Kishimoto H, Sprent J, Burakoff S, Carpenter C, Milford E, McKay D: **Signaling T-cell survival and death by IL-2 and IL-15.** *Am J Transplant* 2005, **5**:2623-2631.
- Sanchez-Sanchez N, Riol-Blanco L, de la Rosa G, Puig-Kroger A, Garcia-Bordas J, Martin D, Longo N, Cuadrado A, Cabanas C, Corbi AL, et al.: **Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells.** *Blood* 2004, **104**:619-625.

18. Fernandez N, Renedo M, Garcia-Rodriguez C, Sanchez Crespo M: **Activation of monocytic cells through Fc gamma receptors induces the expression of macrophage-inflammatory protein (MIP)-I alpha, MIP-I beta, and RANTES.** *J Immunol* 2002, **169**:3321-3328.
19. Bade B, Boettcher HE, Lohrmann J, Hink-Schauer C, Bratke K, Jenne DE, Virchow JC Jr, Luttmann W: **Differential expression of the granzymes A, K and M and perforin in human peripheral blood lymphocytes.** *Int Immunol* 2005, **17**:1419-1428.
20. Adrain C, Murphy BM, Martin SJ: **Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B.** *J Biol Chem* 2005, **280**:4663-4673.
21. Veugelers K, Motyka B, Frantz C, Shostak I, Sawchuk T, Bleackley RC: **The granzyme B-serglycin complex from cytotoxic granules requires dynamin for endocytosis.** *Blood* 2004, **103**:3845-3853.
22. Brossard C, Semichon M, Trautmann A, Bismuth G: **CD5 inhibits signaling at the immunological synapse without impairing its formation.** *J Immunol* 2003, **170**:4623-4629.
23. Choudhuri K, Kearney A, Bakker TR, van der Merwe PA: **Immunology: how do T cells recognize antigen?** *Curr Biol* 2005, **15**:R382-R385.
24. Hahn WC, Menu E, Bothwell AL, Sims PJ, Bierer BE: **Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59.** *Science* 1992, **256**:1805-1807.
25. Badour K, Zhang J, Siminovitch KA: **The Wiskott-Aldrich syndrome protein: forging the link between actin and cell activation.** *Immunol Rev* 2003, **192**:98-112.
26. Posselt AM, Vincenti F, Bedolli M, Lantz M, Roberts JP, Hirose R: **CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients.** *Transplantation* 2003, **76**:190-195.
27. Lanier LL: **NK cell recognition.** *Annu Rev Immunol* 2005, **23**:225-274.
28. Wex T, Buhling F, Wex H, Gunther D, Malfertheiner P, Weber E, Bromme D: **Human cathepsin W, a cysteine protease predominantly expressed in NK cells, is mainly localized in the endoplasmic reticulum.** *J Immunol* 2001, **167**:2172-2178.
29. Fujii N, Hiraki A, Ikeda K, Ohmura Y, Nozaki I, Shinagawa K, Ishimaru F, Kiura K, Shimizu N, Tanimoto M, Harada M: **Expression of minor histocompatibility antigen, HA-1, in solid tumor cells.** *Transplantation* 2002, **73**:1137-1141.
30. Sullivan TP, Dearaujo T, Vincek V, Berman B: **Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping.** *Dermatol Surg* 2003, **29**:1181-1186.
31. Iwasaki A, Medzhitov R: **Toll-like receptor control of the adaptive immune responses.** *Nat Immunol* 2004, **5**:987-995.
32. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S: **Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.** *Nat Immunol* 2002, **3**:196-200.
33. Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, Skarica M, Brockstedt D, Dubensky TW, Stins MF, Lanier LL, et al.: **Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity.** *Nat Med* 2006, **12**:207-213.
34. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S: **Tumors as elusive targets of T cell-directed immunotherapy.** *Trends Immunol* 2003, **24**:335-342.
35. Bowen DG, Walker CM: **Adaptive immune responses in acute and chronic hepatitis C virus infection.** *Nature* 2005, **436**:946-952.
36. Smith MW, Yue ZN, Korth MJ, Do HA, Boix L, Fausto N, Bruix J, Carithers RL Jr, Katze MG: **Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers.** *Hepatology* 2003, **38**:1458-1467.
37. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, Slavatierra O Jr: **Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling.** *N Engl J Med* 2003, **349**:125-138.
38. Panelli MC, Wang E, Phan G, Puhlman M, Miller L, Ohnmacht GA, Klein H, Marincola FM: **Genetic profiling of peripheral mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration.** *Genome Biol* 2002, **3**:RESEARCH0035.
39. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA: **Interleukin-32: a cytokine and inducer of TNFalpha.** *Immunity* 2005, **22**:131-142.
40. Hicks AM, Riedlinger G, Willingham MC, Alexander-Miller MA, von Kap-Herr C, Pettenati MJ, Sanders AM, Weir HM, Du W, Kim J, et al.: **Transferable anticancer innate immunity in spontaneous regression/complete resistance mice.** *Proc Natl Acad Sci USA* 2006, **103**:7753-7758.
41. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM: **High fidelity mRNA amplification for gene profiling.** *Nat Biotechnol* 2000, **18**:457-459.
42. Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham A, Kim JM, Yoon DY, Dinarello CA, Kim SH: **IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism.** *Proc Natl Acad Sci USA* 2005, **102**:16309-16314.
43. Monsurro V, Wang E, Yamano Y, Migueles SA, Panelli MC, Smith K, Nagorsen D, Connors M, Jacobson S, Marincola FM: **Quiescent phenotype of tumor-specific CD8+ T cells following immunization.** *Blood* 2004, **104**:1970-1978.
44. Wang E, Panelli MC, Zavaglia K, Mandruzzato S, Hu N, Taylor PR, Seliger B, Zanollo P, Freedman RS, Marincola FM: **Melanoma-restricted genes.** *J Transl Med* 2004, **2**:34.
45. Richwald GA: **Imiquimod.** *Drugs Today (Barc)* 1999, **35**:497-511.
46. Dahl MV: **Imiquimod: a cytokine inducer.** *J Am Acad Dermatol* 2002, **47**:S205-S208.
47. Matzinger P: **Introduction to the series. Danger model of immunity.** *Scand J Immunol* 2001, **54**:2-3.
48. Panelli MC, Riker A, Kammula U, Wang E, Lee KH, Rosenberg SA, Marincola FM: **Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.** *J Immunol* 2000, **164**:495-504.
49. Kammula US, Marincola FM, Rosenberg SA: **Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination.** *J Natl Cancer Inst* 2000, **92**:1336-1344.
50. Fuchs EJ, Matzinger P: **Is cancer dangerous to the immune system?** *Semin Immunol* 1996, **8**:271-280.
51. Monsurro V, Wang E, Panelli MC, Nagorsen D, Jin P, Katia Z, Smith K, Ngalmé Y, Even J, Marincola FM: **Active-specific immunization against melanoma: is the problem at the receiving end?** *Sem Cancer Biol* 2003, **13**:473-480.
52. Marincola FM: **A balanced review of the status of T cell-based therapy against cancer.** *J Transl Med* 2005, **3**:16.
53. Urošević M, Dummer R, Conrad C, Beyeler M, Laine E, Burg G, Giliet M: **Disease-independent skin recruitment and activation of plasmacytoid dendritic cells following imiquimod treatment.** *J Natl Cancer Inst* 2005, **97**:1143-1153.
54. Torres A, Storey L, Anders M, Miller RL, Bulbulian BJ, Jin J, Raghavan S, Lee J, Slade HB, Birmachou W: **Immune-mediated changes in actinic Keratosis following topical treatment with Imiquimod 5% cream.** *J Transl Med* 2007 in press.
55. Rechtssteiner G, Warger T, Osterloh P, Schild H, Radsak MP: **Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod.** *J Immunol* 2005, **174**:2476-2480.
56. Wenzel J, Uerlich M, Haller O, Bieher T, Tueting T: **Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.** *J Cutan Pathol* 2005, **32**:257-262.
57. Craft N, Bruhn KW, Nguyen BD, Prins R, Lin JW, Liao LM, Miller JF: **The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant *Listeria monocytogenes* vaccine.** *J Immunol* 2005, **175**:1983-1990.
58. Wang E, Marincola FM: **Amplification of small quantities of mRNA for transcript analysis.** In *DNA arrays: A Molecular Cloning Manual* Edited by: Bowtell D, Sambrook J. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2002:204-213.
59. Wang E: **RNA amplification for successful gene profiling analysis.** *J Transl Med* 2005, **3**:28.
60. **National Cancer Institute, Center for Cancer Research: mAdb GAL Files (Hs-CCDTM17 5 k-lpx gal)** [http://nci.array.nci.nih.gov/gal_files/gal_custom_current.shtml]
61. Eisen MB, Spellman PT, Brown PO, Botstein D: **Cluster analysis and display of genome-wide expression patterns.** *Proc Natl Acad Sci USA* 1998, **95**:14863-14868.
62. Ross DT, Scherf U, Eisen MB, Perou CM, Rees CA, Spellman PT, Iyer V, Jeffery SS, van de Rijn M, Waltham M, et al.: **Systematic variation in gene expression patterns in human cancer cell lines.** *Nature Genetics* 2000, **24**:227-235.

63. **DAVID Bioinformatics Resource 2006** [<http://david.abcc.ncifcrf.gov/>]
64. **GeneCards Database** [<http://www.genecards.org/index.shtml>]
65. **COPE: Cytokines and Cells Online Pathfinder Encyclopedia** [<http://www.copewithcytokines.de>]
66. **Bioinformatic Harvester Database** [<http://harvester.embl.de/harvester/P599/P59901.htm>]
67. **Biomedical Research Support Facilities, University of Pittsburgh** [<http://www.pitt.edu/~rsup/OligoCalc.html>]
68. Livak KJ, Schmittgen TD: **Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.** *Methods* 2001, **25**:402-408.
69. **National Cancer Institute, Biometric Research Branch: BRB Array Tools** [<http://linus.nci.nih.gov/BRB-ArrayTools.html>]
70. Simon R, Lam A, Li MC, Ngan M, Menezes S, Zhao Y: **Analysis of gene expression data using BRB-Array Tools.** *Cancer Informatics* 2007 in press.
71. **NCBI: Gene Expression Omnibus (GEO)** [<http://www.ncbi.nlm.nih.gov/geo/>]

comment

reviews

reports

deposited research

refereed research

interactions

information